Solid Biosciences Inc. develops precision genetic medicines for rare neuromuscular and cardiac diseases. The company’s recurring news centers on its gene therapy portfolio, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for TNNT2-mediated dilated cardiomyopathy.
Company updates also cover clinical data from Duchenne studies, regulatory designations for SGT-003, scientific presentations in gene and cell therapy, capital-raising activity, inducement equity grants, investor conference participation, shareholder voting matters, and governance disclosures.
Solid Biosciences (Nasdaq: SLDB) has announced the pricing of an underwritten public offering of 21,739,131 shares at $5.75 per share, generating total gross proceeds of $125 million before expenses. An option allows underwriters to purchase an additional 3,260,869 shares. The offering is expected to close on March 23, 2021, subject to customary conditions. Proceeds will fund research and development for SGT-001 and other corporate purposes. The offering involves an effective registration statement filed with the SEC.
Solid Biosciences announced a public offering of $85 million in common stock to enhance funding for its Duchenne muscular dystrophy therapies. The offering is underwritten and includes a 30-day option for underwriters to purchase an additional 15%. Jefferies, SVB Leerink, and Piper Sandler are managing the offering, which is subject to market conditions. The shares are offered under an effective registration statement filed with the SEC. No assurance can be given regarding the offering's completion or its terms due to market uncertainties.
Solid Biosciences Inc. (Nasdaq: SLDB) has reported promising interim data from its IGNITE DMD Phase I/II trial of SGT-001, a gene therapy for Duchenne muscular dystrophy. Data from six patients indicate improvements in functional endpoints, including scores from the North Star Ambulatory Assessment and the 6-Minute Walk Test, with some patients showing a mean improvement in walking distance by over 37 meters. Recent dosing of a seventh patient was successful, with manageable side effects. The next steps involve continued enrollment and evaluation of additional patient outcomes.
Solid Biosciences (Nasdaq: SLDB) announced the grant of an inducement award to its new Chief Legal Officer, Erin Brennan, as approved by independent directors on February 25, 2021. The inducement award consists of an option to purchase 325,000 shares of common stock at an exercise price of $8.52 per share, with a ten-year term and vesting in four equal annual installments. This appointment aims to strengthen the company's leadership in developing therapies for Duchenne muscular dystrophy.
Solid Biosciences (Nasdaq: SLDB) announces key leadership changes aimed at advancing therapies for Duchenne muscular dystrophy. Erin Powers Brennan joins as Chief Legal Officer, while Joel Schneider is promoted to Chief Operating Officer. The company also expands its Board of Directors with the appointments of Clare Kahn and Georgia Keresty, both experienced in the healthcare and pharmaceutical sectors. These moves are expected to enhance the company's strategic direction and operational capabilities in developing its lead gene therapy candidate, SGT-001, and improving patient outcomes.
Solid Biosciences (Nasdaq: SLDB) announced the presentation of one-year efficacy and safety data from the ongoing IGNITE-DMD Phase I/II study of SGT-001 microdystrophin gene therapy for Duchenne muscular dystrophy. Principal Investigator Dr. Barry Byrne will present the findings at the 2021 MDA Virtual Clinical & Scientific Conference on March 18 at 4 PM ET. Additionally, a symposium on Real World Outcomes Measures will take place on the same day. A conference call discussing interim data and financial results is scheduled for March 15 at 4:30 PM ET.
Solid Biosciences (Nasdaq: SLDB) has announced participation in two upcoming investor conferences. Chief Technology Officer Joel Schneider and Acting Chief Medical Officer Cathryn Clary will present at the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 1:40 p.m. ET, and at the Barclays Global Healthcare Conference on March 11, 2021, at 9:45 a.m. ET. Live webcasts will be available on the company’s investor relations website, with replays also accessible afterwards. Solid Biosciences aims to develop therapies for Duchenne muscular dystrophy through its lead gene therapy candidate, SGT-001.
Solid Biosciences, a life sciences company focused on therapies for Duchenne muscular dystrophy, announced that CEO Ilan Ganot will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 8:20 am ET. Following the presentation, leadership will be available for Q&A. Institutional investors interested in meetings can contact their J.P. Morgan representative. A live webcast will be accessible on the company's website, with a replay available for 30 days.
Solid Biosciences (Nasdaq: SLDB) announced a $90 million private placement agreement with institutional and accredited investors, set to close around December 15, 2020. The transaction involves issuing 24,324,320 shares at $3.70 each, with investment participation from firms like Suvretta Capital and RA Capital. Proceeds will fund research and development, particularly for SGT-001, and support general corporate purposes. The company plans to file a registration statement with the SEC to register the resale of the shares within 120 days post-closing.
Solid Biosciences (SLDB) reported financial results for Q3 2020 and provided a business update, including the lifting of the FDA clinical hold on the IGNITE DMD trial, with resuming expected in Q1 2021. The company announced a collaboration with Ultragenyx to develop new gene therapies for Duchenne muscular dystrophy, which includes a $40 million investment and potential milestone payments up to $255 million. R&D expenses decreased to $16 million in Q3 2020 from $22.8 million in Q3 2019, while net loss reduced to $21.2 million.